Aura Biosciences, Inc. Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year
Aura Biosciences, Inc. (AURA) had Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year of $1.72 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear · last filed 2026-08-11
- 2026-06-30: Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year $1.72M.
- 2026-03-31: Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year $2.56M.
- 2025-09-30: Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year $841.00K.
- 2025-06-30: Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year $1.67M.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $1.72M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $2.56M 10-Q · filed 2026-05-11 |
| 2025-09-30 | $841.00K 10-Q · filed 2025-11-13 |
| 2025-06-30 | $1.67M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $2.49M 10-Q · filed 2025-05-15 |
| 2024-09-30 | $816.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $1.24M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $2.07M 10-Q · filed 2024-05-09 |
| 2023-09-30 | $793.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $1.57M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $2.34M 10-Q · filed 2023-05-11 |
| 2022-09-30 | $768.00K 10-Q · filed 2022-11-10 |
| 2022-06-30 | $319.00K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $473.00K 10-Q · filed 2022-05-12 |
| 2021-09-30 | $153.00K 10-Q · filed 2021-11-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |